703 related articles for article (PubMed ID: 11650305)
1. Ethical responsibilities of physicians in their dealings with pharmaceutical companies.
Royal College of Physicians and Surgeons of Canada. Biomedical Ethics Committee
Ann R Coll Physicians Surg Can; 1990 Jan; 23(1):45-8. PubMed ID: 11650305
[No Abstract] [Full Text] [Related]
2. Physicians and the pharmaceutical industry.
Canadian Medical Association
CMAJ; 1992 Feb; 146(3):388A-C. PubMed ID: 11654903
[No Abstract] [Full Text] [Related]
3. Is post-marketing drug follow-up research or advertising?
Weiss GB; Winslade WJ
IRB; 1987; 9(4):10-1. PubMed ID: 11649947
[No Abstract] [Full Text] [Related]
4. Guidelines on gifts to physicians from industry: an update.
American Medical Association. Council on Ethical and Judicial Affairs
Food Drug Law J; 1992; 47(4):445-58. PubMed ID: 11654909
[No Abstract] [Full Text] [Related]
5. Pitching doctors.
Wilkes MS; Shuchman M
N Y Times Mag; 1989 Nov; ():88, 90, 126, 128-129. PubMed ID: 11650264
[No Abstract] [Full Text] [Related]
6. The case for per patient payments.
Lewis JP
IRB; 1988; 10(5):9. PubMed ID: 11650075
[No Abstract] [Full Text] [Related]
7. The relationship between physicians and the pharmaceutical industry: a report of the Royal College of Physicians.
Royal College of Physicians
J R Coll Physicians Lond; 1986 Oct; 20(4):3-10. PubMed ID: 11643936
[No Abstract] [Full Text] [Related]
8. Pushing drugs to doctors.
Consum Rep; 1992 Feb; 57(2):87-94. PubMed ID: 11651202
[No Abstract] [Full Text] [Related]
9. Two cheers for the CMA's new guidelines on drug company-MD relations The CMA's MD-drug industry guidelines offer advice, nothing more.
Rapp MS; Woollard R
CMAJ; 1991 Dec; 145(11):1497-9. PubMed ID: 11649303
[No Abstract] [Full Text] [Related]
10. Why I oppose drug company payment of physician/investigators on a per patient/subject basis.
Roizen R
IRB; 1988; 10(1):9-10. PubMed ID: 11658990
[No Abstract] [Full Text] [Related]
11. Code of ethics: CMA policy summary.
Canadian Medical Association
CMAJ; 1987 Oct; 137(8):760A-D. PubMed ID: 11658965
[No Abstract] [Full Text] [Related]
12. A doctor's drug studies turn into fraud.
Eichenwald K; Kolata G
N Y Times Web; 1999 May; ():A1, A16. PubMed ID: 11647660
[No Abstract] [Full Text] [Related]
13. The CMA's MD-drug industry guidelines offer advice, nothing more.
Woollard R
CMAJ; 1991 Dec; 145(11):1498-9. PubMed ID: 11649304
[No Abstract] [Full Text] [Related]
14. Drug trials hide conflicts for doctors.
Eichenwald K; Kolata G
N Y Times Web; 1999 May; ():1, 34. PubMed ID: 11648114
[No Abstract] [Full Text] [Related]
15. In search of funding: the clinical investigator and the drug company; Commentary: why researchers need not be demoralized.
Siris ES; Burrell CD
IRB; 1983; 5(6):1-5. PubMed ID: 11649526
[No Abstract] [Full Text] [Related]
16. Dilemmas in paying for clinical research: the view from the IRB.
Lind SE
IRB; 1987; 9(2):1-5. PubMed ID: 11649900
[No Abstract] [Full Text] [Related]
17. The influence of a professional organization on physician behavior.
Orentlicher D
Albany Law Rev; 1994; 57(3):583-605. PubMed ID: 11652855
[No Abstract] [Full Text] [Related]
18. All expenses paid, Doctor.
Greenberg DS
Lancet; 1990 Dec 22-29; 336(8730):1568-9. PubMed ID: 11653929
[No Abstract] [Full Text] [Related]
19. General Council to consider amendments to CMA policy on MDs' relationships with drug industry.
Williams JR
CMAJ; 1993 Aug; 149(3):335-7. PubMed ID: 11659649
[No Abstract] [Full Text] [Related]
20. Patients for hire, doctors for sale.
N Y Times Web; 1999 May; ():A12. PubMed ID: 11648117
[No Abstract] [Full Text] [Related]
[Next] [New Search]
